Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin + irinotecan + bevacizumab followed by docetaxel + bevacizumab in advanced gastric cancer
2008-006128-79Phase 2Completed
- Sponsor
- AGMT
- Start
- Mar 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, irinotecan, bevacizumab and docetaxel in gastric cancer (GC), sponsored by AGMT. Primary endpoint: Efficacy (Response Rate). Started Mar 2009; status: completed.
02
Drugs
oxaliplatinirinotecanbevacizumabdocetaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2008-006128-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006128-79.